Director​/Senior Director, Supply Chain

Who We Are:

Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life‑changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.

We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the FDA in the third quarter of 2026.

Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic‑clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.

In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting, and continue to advance an early‑stage pipeline of novel therapeutic candidates. In 2025, we initiated Phase 1 trials for XEN
1701 (targeting Nav
1.7) and XEN
1120 (targeting Kv7). Nav
1.7 and Kv7 are important pain targets, and data from these Phase 1 studies are expected in 2026 to support Phase 2 proof‑of‑concept studies in acute pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.

We are seeking a Director/Senior Director, Supply Chain to lead and manage the key strategic activities from clinical development through commercial readiness and launch. This role is accountable for building scalable, compliant, and resilient supply chain capabilities while operating effectively in an environment of ambiguity, rapid change, and aggressive timelines. The ideal candidate will be a strategic partner working with cross‑functional leaders to support this critical next step for Xenon.

The ideal candidate can balance speed with accuracy, apply critical thinking with the information available, and ensure integrated planning, capacity management, systems, and governance as programs advance toward commercialization. This leader will be both strategic and hands‑on, capable of setting direction while driving execution across multiple programs and external partners.

This position reports to the Executive Director, Supply Chain and will be based out of Boston, MA, USA in our Needham office. We may consider remote locations for exceptional candidates. The level of the position will be commensurate with the candidate’s education and industry experience. Hybrid positions require a minimum of two onsite days per week.

• Lead and manage end‑to‑end supply chain strategy and execution across clinical, pre‑commercial, and commercial phases, including launch and post‑launch stabilization. Design and implement scalable supply chain models that evolve with program maturity, from early clinical supply through first commercial launches and lifecycle expansion. Anticipate and proactively manage risks related to capacity, inventory, timelines, cost, and compliance during phase transitions.
• Lead integrated demand, supply, and inventory planning across clinical and commercial horizons, ensuring alignment with development milestones, launch timing, and evolving demand forecasts. Maintain an in‑depth understanding of external manufacturing site capacities, capabilities, and supply risks across the network.…